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Objective/background: Management of Wilms tumor (WT) in children depends on a multidisci-
plinary approach to treatment, and outcomes have significantly improved as reported by coop-
erative group clinical trials. Here, we review the clinical outcomes of patients with WT and
identify challenges and barriers encountered in multidisciplinary management outside of coop-
erative clinical trials.
Methods: We retrospectively reviewed the clinical records of 35 children with WT treated
between April 2002 and June 2013 at the Children’s Cancer Institute in Lebanon.
Results: Upfront resection was performed in 23 cases. Biopsies were performed for Stage V
tumors (n = 4), those with unresectable tumors or inferior vena caval thrombus (n = 5), and
patients who had partial surgery performed elsewhere prior to presentation (n = 2). One patient
died due to toxicity prior to surgery. The tumor was Stage I in eight patients, Stage II in five
patients, Stages III and IV in nine patients each, and bilateral (Stage V) in four patients. Adher-
ence to The National Wilms Tumor Study-5 recommendations was adequate. At the time of
analysis, 30 patients were free of disease and four patients had relapse—all having metastatic
disease initially.
Conclusion: The National Wilms Tumor Study-5 therapy resulted in favorable outcomes in chil-
dren with nonmetastatic Wilms tumor in the setting of a multidisciplinary approach to therapy
and resolution of financial barriers to medical care. Upstaging due to prior intervention and
lung radiation therapy to all those with computed tomography-detected lung nodules may both
Wilms tumor management and outcome 21have resulted in overtreatment of a subset of patients. Finally, the relatively high incidence of
bilateral tumors suggests the need for further genetic and molecular studies in this patient
population.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Nephroblastoma (Wilms tumor; WT) is the most common
pediatric renal tumor [1], thought to arise from foci of
persistent metanephric cells referred to as nephrogenic
rests or nephroblastomatosis [2]. The outcome of WT has
improved significantly over the past few decades; the
5-year survival rate has improved from 20% in the 1960s
to over 90% in the current decade [3–5]. This improvement
is due primarily to a multidisciplinary approach to treat-
ment, and to a series of cooperative clinical trials aiming
at optimizing therapy and risk stratification, led by two
large study groups: the North American Children’s Oncol-
ogy Group via The National Wilms Tumor Study (NWTS)
group, and the European Societe Internationale D’oncolo-
gie Pediatrique (SIOP) group. However, despite the impres-
sive improvements in outcome, retrospective reviews of
outcomes from developing countries have shown poorer
results [6–19]. Factors that are thought to contribute to
this disparity include late presentation, malnutrition, pov-
erty leading to abandonment of treatment, and lack of
multidisciplinary collaboration [6–19]. In this study we
aimed to determine the characteristics and outcomes of
patients with WT treated at a multidisciplinary center in
Lebanon, and to identify successes and barriers in imple-
menting established treatment protocols and risk stratifi-
cation for this disease when applied in a multidisciplinary
setting outside of a cooperative clinical trial, and after
financial barriers to therapy are overcome by a local
fundraising body.
Materials and methods
This retrospective study was approved by the Institutional
Review Board at the American University of Beirut Medical
Center, Beirut, Lebanon. All patients with Wilms tumor
treated at the Children’s Cancer Institute at the American
University of Beirut Medical Center between April 2002
and June 2013 were identified, and the medical records
were retrospectively reviewed. Data collected included
the age at diagnosis, sex, tumor site, size, extent, stage,
treatment received, complications, and outcome. The ini-
tial workup for all patients included history, physical exam-
ination, and laboratory blood tests including kidney function
tests. Staging studies included computed tomography (CT)
scans of the chest, abdomen, and pelvis, with oral and intra-
venous contrast administration, and in some cases plain
X-ray of the chest. Nephrectomy and complete tumor resec-
tion was performed upfront whenever feasible; upfront
tumor biopsy was restricted to patients with bilateral
tumors or those who had extensive regional disease preclud-
ing attempts at complete resection. Patients with upfrontbiopsy received neo-adjuvant chemotherapy, with delayed
surgical resection.
Risk stratification and treatment planning were unified
and based on the NWTS-5 protocol. Per this plan, patients
with Stage I and favorable histology Stage II tumors receive
regimen EE4A consisting of vincristine and actinomycin-D
for 18 weeks [20]; those with unfavorable histology Stage
II tumors or favorable histology Stage III and IV tumors
receive regimen DD4A consisting of vincristine,
actinomycin-D, and doxorubicin for 24 weeks [20]; and
those with Stage II–IV tumors with diffuse anaplasia
received regimen I which includes vincristine, cyclophos-
phamide, etoposide, and doxorubicin for 24 weeks [21].
Patients received radiation therapy (flank, whole abdomen,
lung, metastatic sites) as per the NWTS-5 protocol; specifi-
cally, patients with Stage III focal tumor received focal
abdominal radiation to 10.8 Gy; those with tumor spill, pos-
itive peritoneal cytology, or extensive lymphadenopathy
received whole abdomen radiation to 10.8 Gy; patients with
lung metastases received radiation to the lungs to 12 Gy,
and those with bulky extra-abdominal metastases received
radiation to that site, as needed. After finishing treatment,
all patients were followed up regularly with physical exam-
ination, imaging with ultrasonography of the abdomen, CT
of the chest for those with initial Stage IV disease, and chest
X-ray for patients with Stage I–III disease, as well as urine
analysis and serum blood urea nitrogen and creatinine
levels.
Data was analyzed using the SPSS software version 22
(SPSS Inc., Chicago, IL, USA). Kaplan–Meier survival curves
were generated to estimate overall survival (OS), event free
survival (EFS), and Stage specific survival estimates. OS was
defined as time from initial diagnosis to time of death from
any cause or to most recent follow-up. EFS was defined as
time from initial diagnosis to first relapse, death from any
cause, or most recent follow-up, whichever occurred first.Results
Thirty-five children were diagnosed with nephroblastoma
and represented 4% of all patients diagnosed with cancer
during the study period. Patient characteristics are shown
in Table 1. Male to female ratio was 1:1.7, and the mean
age at diagnosis was 3.9 ± 3.1 years (median 3 years, range,
0.6–16 years). Stage distribution is shown in Table 1; local
Stage III disease was due to positive abdominal lymph nodes
by histology in six patients (3 of whom also had metastatic
disease), intra-operative tumor spillage in two patients,
nonresectable tumor in five patients, pre-operative tumor
rupture due to trauma in one patient, and upstaging due
to incomplete operation prior to referral in two patients.
Three patients had tumor thrombus involving the inferior
22 W. Rabeh et al.vena cava at diagnosis, and one patient had thrombus
reaching renal vein but with patent inferior vena cava.
Twenty-three patients (66%) had an upfront nephrec-
tomy followed by Stage specific chemotherapy and radio-
therapy as per the North American NWTS-5 protocol.
Eleven patients (31%) had an upfront biopsy followed by
definitive surgery at a median time of 6 weeks after initia-
tion of chemotherapy (range, 2–15 weeks). One patient
died due to disseminated intravascular coagulation prior
to timing of surgery. All remaining patients underwent suc-
cessful tumor resection. Thirty patients underwent unilat-
eral nephrectomy, and two of them also required partial
diaphragmatic resection to achieve negative margins. For
the four patients with bilateral tumors, two underwent
bilateral partial nephrectomies, and two required unilateral
radical nephrectomy and partial nephrectomy on the other
side. One patient had diffuse anaplasia; all others had favor-
able histology tumors. Eight patients received whole
abdominal radiation therapy, and six received flank/tumor
bed radiation. Five patients received radiation therapy to
the lungs, and one received additional radiation therapy
to liver metastases. Planned chemotherapy was adminis-
tered successfully, with minimal delays in schedule. Compli-
cations of chemotherapy are shown in Table 2. Surgical
complications were infrequent: two patients developed
functional intestinal obstruction, which was managed con-
servatively and resolved without long-term sequelae. In
general, patients were observed in the pediatric intensiveTable 1 Patient characteristics
Variable
Sex Male
Kidney site Right
Left
Bilateral
Tumor histology Favorable
Anaplastic
Local lymph nodes Positive
Metastasis Lungs
Multiple organs (liver,
Distant lymph nodes
Stage I
II
III
IV
V
Nephrectomy Upfront
Delayed (initial biopsy)
Nonea
Radiotherapy (local) Stage III
Stage IV
Stage V
Note. Data are presented as n (%).
a One patient died of disseminated intravascular coagulation prior tcare unit for at least 2 days after nephrectomy. Of note,
one patient developed chronic renal failure during treat-
ment, due to focal segmental glomerulosclerosis occurring
in the remaining noninvolved kidney. This child was found
to have Denys-Drash syndrome using WT1 gene mutation
analysis, and is currently on chronic dialysis awaiting renal
transplantation.
The treatment outcomes are shown in Table 2. At the
time of analysis, 30 patients (86%) were alive; all were free
of disease at a median follow-up time of 58 months from
diagnosis (range, 23–134 months). Four patients had dis-
ease relapse at a median time of 8.8 months (range, 7.1–
12.2 months) from initial diagnosis. Notably, all four
patients who had relapse had initial metastatic (Stage IV)
disease. Relapse occurred in the lungs in all four patients;
two patients also had synchronous liver metastases and
one had synchronous metastasis to the uterus. All four
patients who relapsed died due to disease progression
despite second-line therapy. The 3-year OS and EFS esti-
mates for all analyzed patients were 88.6% and 85.7%,
respectively (Figure 1A and B). When analyzed by Stage,
patients with Stage I, II, and V disease had 100% 3-year OS,
whereas patients with Stage III disease had a 3-year OS of
90%, and those with Stage IV disease had a 3-year OS of
67% (Figure 1C). EFS rates followed a similar pattern,
with 3-year EFS for patients with Stages I, II, and V disease
at 100%, Stage III disease at 90%, and Stage IV disease at
55.6%.No. of patients (N = 35)
13 (37)
19 (54)
12 (34)
4 (12)
34 (97)
1 (3)
11 (31)
7 (20)
bone, and lung) 1 (3)
1 (3)
8 (23)
5 (14)
9 (26)
9 (26)
4 (11)
23 (66)
11 (31)
1 (3)
8 (23)
7 (20)
0 (0)
o surgery.
Table 2 Complications and outcomes
No. (N = 35)
Treatment complications Neutropenic fever 4 (12)
Severe diarrhea 5 (14)
Febrile urinary tract infection 5 (14)
Varicella infection 4 (12)
Disseminated intravascular coagulation 1 (3)
Functional intestinal obstruction 2 (6)
Outcome Continued complete remission 30 (86)
Relapse 4 (12)
Deatha 5 (14)
Note. Data are presented as n (%).
a All patients who relapsed died of disease progression.
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The NWTS studies have shown 2-year EFS of 94.9% and an OS
of 98.7% for Stage I disease, 8-year EFS of 83.6% and an OS of
93.8% for Stage II disease, 8-year EFS of 88.9% and an OS of
93% for Stage III disease, and a 2-year EFS of 80.6% and an OS
of 89.5% for Stage IV disease [22,23]. Similarly, the SIOP
study group has shown a 5-year EFS of 92% for Stage I and
node-negative Stage II disease, with an EFS of 82% for
node-positive Stage II and III tumors, and a 5-year EFS of
72.3% with an OS of 83.3% for Stage IV disease [24–26].
Other developed countries have shown similar results
[27–32]. In our series, the 3-year EFS and OS were 85.7%
and 88.6% respectively. Although we describe a smallFigure 1 (A) Overall survival estimate; (B) event-free survival esti
event-free survival estimate stratified by tumor stage. Note. St = stnumber of patients limiting statistical comparisons, it seems
that our experience shows similar outcome rates for
patients with Stage I, II, III, and V disease, while patients
with metastatic disease fared worse than published results
from cooperative group trials. In general, patient character-
istics at presentation did not differ from those published
from other centers, taking the variable sample sizes into
account. We observed a female preponderance, similar to
what has been observed in the NWTS and SIOP studies
[24,26]. The median age at presentation was 36 months,
which is comparable to what has been observed in other
studies [9,11–13,15–18,33,34]. The right kidney was more
commonly affected than the left in our study. In our cohort
of patients, treatment was not interrupted and there was no
abandonment—a very important consideration that affectsmate for the entire group; (C) overall survival estimate; and (D)
age.
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19]. This is likely due to the fact that all financial barriers
were resolved by complete financial coverage of treatment
costs by a local fundraising body, which allowed patients
with poor socioeconomic status and lack of third-party
insurance to continue therapy without major interruptions.
While the apparently worse outcome of children with Stage
IV disease in our study could be due to a difference in tumor
biology, it should be kept in mind that the small number of
patients analyzed limits the significance of this observed
difference.
Other issues in treatment allocation and delivery were
noted that deserve mentioning. Firstly, upstaging was nec-
essary in two of 35 patients (6%) due to inappropriate sur-
gery before patient referral to the oncologist. This
upstaging resulted in treatment as Stage III disease, with
more intensive chemotherapy (DD4A regimen) and whole
abdomen radiation therapy. Even after accounting for
patients who had their disease upstaged due to inadequate
or unclear surgical details prior to referral, we still had a
high rate of patients who presented with late Stage disease
(III and IV), compared with developed countries
[17,26,27,29]. This is in fact similar to what has been
observed in most low- and middle-income countries
[7,9,11,12,14,16,33,35]. Whether this is an indication of
delayed presentation or more aggressive tumor biology, still
needs to be determined.
We also noted that all patients in our series had disease
staging based on chest CT and not chest X-ray, and all those
with lung nodules detected with CT scan received Stage IV-
directed therapy (DD-4A) as well as radiation therapy to the
lungs. While one study showed that three-drug regimen for
CT-only metastases can improve EFS but not OS [36], in
other studies patients with CT-only lung metastases in the
setting of low-stage primary tumors were shown to be ade-
quately treated with a two-drug regimen [37,38]. Most
patients with metastases, however, had local Stage III
disease, and therefore treatment regimen included anthra-
cyclines. The benefit of lung radiation in patients with
CT-only lung metastases is still unclear [36,38] and may con-
tribute to significant long-term side effects [39–41]. Thus,
further efforts should be made to ensure discussion of such
issues in multidisciplinary meetings when individualized
therapy decisions are made.
Finally, the rate of bilateral tumors (11% of our patients)
seems higher than that observed in the NWTS and SIOP
cohorts, as well as other reported series [7,9,12–14,16,19,
29,3,32,34–36,42]. While the reasons for this finding are
unclear, and taking into consideration the limitation of
our small number of patients, it does raise questions regard-
ing possible predisposition conditions to bilateral tumors in
this population and warrants further future assessment. In
our series, patients with Stage V tumors did very well, which
compares favorably to published results [12,13,16,29,31,3
2,34,42–44]. Three of these patients received DD4A regi-
men and one received EE-4A regimen. All had complete
tumor resection consisting of either bilateral partial
nephrectomies or nephrectomy on one side and partial
nephrectomy on the other. None received radiation
therapy, and all four are in continued Complete Remission
(CR) with normal renal function.Conclusion
Although similar to other developing countries, more than
half of our patients presented with late Stage disease (III
and IV) and the outcome of patients in this study
approached that reported in cooperative trials in developed
countries. This likely represents the effects of a multidisci-
plinary approach to management, availability of a special-
ized pediatric oncology surgeon, availability of prompt
supportive care measures, and financial coverage of treat-
ment contributing to low abandonment rates. Earlier refer-
ral of patients to a tertiary care setting, prior to attempted
surgery, would be expected to further improve outcome and
minimize over-staging of such patients.
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